On September 19, the Food and Drug Administration (FDA) announced the extension of the comment period for the July 2017 public meeting entitled “Administering the Hatch-Waxman Amendments: Ensuring a Balance Between Innovation and Access.” In the notice of public meeting, FDA requested comments concerning administration of the Hatch-Waxman Amendments to the Federal Food, Drug, and Cosmetic Act to help ensure the intended balance between encouraging innovation in drug development and accelerating the availability to the public of lower cost alternatives to innovator drugs is maintained. The Agency is taking this action in response to requests for an extension to allow interested persons additional time to submit comments. Further information can be found in the extension of comment period notice.
How to comment
Please submit electronic or written comments to Docket FDA-2017-N-3615 by November 17, 2017.
No hay comentarios:
Publicar un comentario